Infliximab biosimilar is under clinical development by Celltrion and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

I saw your T-shirt,’ she said, pointing at the Crohn’s & Colitis UK logo emblazoned across my chest. ‘I have Crohn’s. I’ve ...

Some people with ulcerative colitis develop symptoms in other body parts, such as their joints or skin. Crohn’s disease and ulcerative colitis are collectively known as inflammatory bowel ...

Ulcerative colitis is a chronic relapsing and remitting ... Surgery is unavoidable in some cases, but is the treatment of choice in others. While ileal pouch–anal anastomosis offers the prospect ...

Keep an eye out for symptoms like flashing lights, floaters, or rapid vision changes — they’re all red flags. If anything seems off, get to an eye doctor as soon as possible. Treatment depends on the ...

COVID-19 might be a trigger for new ulcerative colitis for some people. It may also be a trigger for symptom flare-ups for people previously diagnosed with UC. COVID-19 is a respiratory illness ...

today announced that the RELIEVE UCCD phase 2b study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn’s disease (CD). RELIEVE UCCD assessed duvakitug, a human IgG1-λ2 ...

You may need topical, oral, or body-wide (systemic) treatments. Even if you have severe psoriasis, there are good ways to manage your flare-ups. You may be able to get rid of your symptoms completely.

UC and CD, the two main types of IBD, are chronic inflammatory conditions of the gastrointestinal (GI) tract resulting in debilitating and persistent symptoms ... patients with ulcerative colitis (UC) ...

Teva Pharmaceuticals and Sanofi announced that their Phase 2b RELIEVE UCCD study met primary endpoints for the treatment of ulcerative colitis (UC ... and persistent symptoms such as abdominal ...